Shionogi Innovation Center for Drug Discovery, Shionogi & Co., Ltd, Kita-21, Nishi-11, Kita-ku, Sapporo 001-0021, Japan.
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4810-5. doi: 10.1016/j.bmcl.2012.05.050. Epub 2012 May 18.
The second-generation synthesis of 3'-hydroxypacidamycin D (2) has been accomplished via an Ugi-four component reaction at a late stage of the synthesis. This approach provided ready access to a range of analogues including diastereomers of the diaminobutylic acid residue and hybrid-type analogues of mureidomycins. Biological evaluations of these analogues indicated that the stereochemistry at the diaminobutylic acid residue has a crucial impact on both the MraY biochemical inhibition and whole-cell antibacterial activity.
第二代 3'-羟基帕西霉素 D(2)的合成都通过 Ugi-四组分反应在合成的后期阶段完成。这种方法提供了广泛的类似物,包括二氨基丁酸残基的非对映异构体和粘肽类抗生素的杂种类似物。对这些类似物的生物学评估表明,二氨基丁酸残基的立体化学对 MraY 生化抑制和全细胞抗菌活性都有至关重要的影响。